Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19

Background. On 11 March, 2020 the World Health Organization declared COVID-19, caused by SARS-CoV-2, a global pandemic with almost 17,000,000 confirmed cases worldwide by the end of July, of which 4,500,000 were in the US. Approximately 20% of patients develop severe disease that can evolve into acu...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasileiou, Spyridoula, Kuvalekar, Manik, Workineh, Aster, Watanabe, Ayumi, Velazquez, Yovana, Lulla, Suhasini, Heslop, Helen E., Mooney, Kimberly, Grimes, Kevin, Carrum, George, Hill, LaQuisa C., Lulla, Premal, Leen, Ann M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
703.Adoptive Immunotherapy: Mechanisms and New Approaches
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330271/
http://dx.doi.org/10.1182/blood-2020-140490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330271/
http://dx.doi.org/10.1182/blood-2020-140490

Ejemplares similares